ATE408004T1 - Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen - Google Patents

Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen

Info

Publication number
ATE408004T1
ATE408004T1 AT03725273T AT03725273T ATE408004T1 AT E408004 T1 ATE408004 T1 AT E408004T1 AT 03725273 T AT03725273 T AT 03725273T AT 03725273 T AT03725273 T AT 03725273T AT E408004 T1 ATE408004 T1 AT E408004T1
Authority
AT
Austria
Prior art keywords
cell lines
serum
growth factors
medium
feeder layer
Prior art date
Application number
AT03725273T
Other languages
English (en)
Inventor
Bertrand Pain
Fabienne Guehenneux
Original Assignee
Vivalis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivalis filed Critical Vivalis
Application granted granted Critical
Publication of ATE408004T1 publication Critical patent/ATE408004T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Feeding And Watering For Cattle Raising And Animal Husbandry (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT03725273T 2002-03-08 2003-03-07 Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen ATE408004T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0202945A FR2836924B1 (fr) 2002-03-08 2002-03-08 Lignees de cellules aviaires utiles pour la production de substances d'interet

Publications (1)

Publication Number Publication Date
ATE408004T1 true ATE408004T1 (de) 2008-09-15

Family

ID=27763651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725273T ATE408004T1 (de) 2002-03-08 2003-03-07 Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen

Country Status (14)

Country Link
US (4) US20040058441A1 (de)
EP (2) EP1992687B1 (de)
JP (2) JP5025888B2 (de)
CN (2) CN100562567C (de)
AT (1) ATE408004T1 (de)
AU (1) AU2003227820B2 (de)
CA (1) CA2478125C (de)
DE (1) DE60323468D1 (de)
DK (1) DK1483369T3 (de)
ES (1) ES2312775T3 (de)
FR (1) FR2836924B1 (de)
PT (1) PT1483369E (de)
SI (1) SI1483369T1 (de)
WO (1) WO2003076601A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
US20060191026A1 (en) 2005-02-18 2006-08-24 Origen Therapeutics, Inc. Tissue specific expression of antibodies in chickens
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
WO2004056977A1 (en) * 2002-12-13 2004-07-08 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
EP1500699A1 (de) * 2003-07-22 2005-01-26 Vivalis Herstellung von Vacciniaviren mit Hilfe adhärenter oder nicht adhärenter Vogelzelllinien
DK1646715T3 (da) 2003-07-22 2010-08-16 Vivalis Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
EP2848692B1 (de) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus-Vektoren für Influenzavirus-Impfstoffe
ATE489965T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
US20090004222A1 (en) * 2004-11-03 2009-01-01 O'hagan Derek Influenza Vaccination
FR2878860A1 (fr) * 2004-12-08 2006-06-09 Vivalis Sa Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes
AU2011253998B2 (en) * 2005-04-11 2014-04-24 Valneva Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
FR2898909A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Combinaison de marqueurs de cellules aviaires
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
MX2009001477A (es) 2006-08-09 2009-02-18 Vivalis Metodo de produccion de un aviar transgenico utilizando celulas progenitoras embrionicas.
EP4585610A3 (de) 2006-09-11 2025-09-24 Seqirus UK Limited Herstellung von influenzavirus-impfstoffen ohne verwendung von eiern
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
CN100443588C (zh) * 2006-12-11 2008-12-17 中国农业科学院北京畜牧兽医研究所 静宁鸡胚成纤维细胞系及其培养方法
EP1985305A1 (de) * 2007-04-24 2008-10-29 Vivalis Aus Entenembryonen gewonnene Stammzellkulturen zur Herstellung von Impfstoffen gegen Viren
EP1995309A1 (de) * 2007-05-21 2008-11-26 Vivalis Rekombinante Proteinproduktion in EBx -Vogelzellen
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
JP5421250B2 (ja) * 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム トリ不死化細胞株
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
JP5653223B2 (ja) * 2008-02-25 2015-01-14 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 連続細胞系の生成方法
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
WO2009132195A1 (en) * 2008-04-23 2009-10-29 Michigan State University Immortal avian cell line and methods of use
ES2539045T3 (es) 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
EP3173097A3 (de) 2009-02-10 2017-07-12 Seqirus UK Limited Influenzaimpfstoffe mit reduzierten anteilen an squalen
CA2752041A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
EA201171032A1 (ru) 2009-02-10 2012-02-28 Новартис Аг Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CA2725435C (en) 2009-12-15 2023-01-03 University Of Saskatchewan Vaccines for inclusion body hepatitis
EP2531592A1 (de) 2010-02-04 2012-12-12 Vivalis Fed-batch-verfahren mit konzentriertem zellkulturmedium zur effizienten produktion von biologischen wirkstoffen bei eb66-zellen
FR2956409A1 (fr) 2010-02-15 2011-08-19 Univ Claude Bernard Lyon Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale
US9494571B2 (en) 2010-03-08 2016-11-15 Novartis Ag Methods of testing for intracellular pathogens
EP2374816B1 (de) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
US9744228B2 (en) 2010-04-07 2017-08-29 Norvartis Ag Method for generating a parvovirus B19 virus-like particle
US9426989B2 (en) 2010-05-06 2016-08-30 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
AU2011276328C1 (en) 2010-07-06 2016-01-21 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201011502D0 (en) 2010-07-08 2010-08-25 Glaxosmithkline Biolog Sa Novel process
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
JP6283223B2 (ja) 2010-09-07 2018-02-21 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 多能性幹細胞を培養するための新規な方法および培養培地
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EP2729165B1 (de) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogene kombinationszusammensetzungen und ihre verwendung
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
US20140348863A1 (en) 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
EP2768528A1 (de) 2011-10-20 2014-08-27 Novartis AG Adjuvierte influenza-b-viren-impfstoffe für kinder
EP2660316A1 (de) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Vogelzelllinie und deren Verwendung bei der Herstellung eines Proteins
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
EP2922570A1 (de) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Präfusionierte rsv-f-trimere
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
FR3008992A1 (fr) * 2013-07-25 2015-01-30 Agronomique Inst Nat Rech Procede de selection d'une lignee cellulaire permissive pour la replication de virus aviaires
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
EP2974739A1 (de) 2014-07-15 2016-01-20 Novartis AG RSVF-Trimerisierungsdomänen
EP3031822A1 (de) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus-Antigene
US11147887B2 (en) 2014-12-17 2021-10-19 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease
US11118238B2 (en) 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
EP3047856A1 (de) 2015-01-23 2016-07-27 Novartis AG Cmv-antigene und ihre verwendungen
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
KR102790570B1 (ko) 2015-07-07 2025-04-04 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
EP3687561A4 (de) 2017-09-01 2021-06-09 The Australian National University Immunregulatorische moleküle und deren verwendung
EP3717505A4 (de) 2017-12-01 2021-12-01 Encoded Therapeutics, Inc. Gentechnisch veränderte dna-bindende proteine
WO2019219649A1 (en) 2018-05-14 2019-11-21 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
MX2020012895A (es) 2018-05-30 2021-05-27 Inst Res Biomedicine Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena.
EP3820884B1 (de) 2018-07-13 2025-09-03 Valneva SE Verfahren zur wiederherstellung und erzeugung eines virus in vogelzellen
US20210292791A1 (en) 2018-10-12 2021-09-23 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
AU2019375450A1 (en) 2018-11-07 2021-06-17 Vivet Therapeutics Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
EP3880809A4 (de) 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus wilson
SG11202104869SA (en) 2018-11-23 2021-06-29 Valneva Se Food products comprising avian stem cells
WO2020234888A1 (en) 2019-05-22 2020-11-26 Hadasit Medical Research Services And Development Ltd. Methods of culturing human pluripotent cells
PL3976798T3 (pl) 2019-05-29 2026-04-07 Encoded Therapeutics, Inc. Kompozycje i sposoby selektywnej regulacji genów
JP7852185B2 (ja) 2019-07-02 2026-04-28 フンダシオン・パラ・ラ・インベスティガシオン・メディカ・アプリカダ ｃＰＬＡ２ｅ誘導剤及びその使用
US20220273789A1 (en) 2019-07-21 2022-09-01 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
JP2022548179A (ja) * 2019-09-10 2022-11-16 バイタル ミート 食品製造のための鳥類幹細胞
EP4061930A1 (de) 2019-11-18 2022-09-28 Seqirus Pty Ltd Verfahren zur herstellung von reassortierenden influenza-viren
CN116390773A (zh) 2020-08-06 2023-07-04 应用医学研究基金会 用于通过基因疗法治疗诸如阿尔茨海默病的Tau蛋白病的病毒颗粒
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
IL301255A (en) 2020-10-09 2023-05-01 UCB Biopharma SRL Nucleic acid structures, viral vectors and viral particles
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
EP4032547A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce abgeleitete fragemente zur hsv therapie
EP4423286A1 (de) 2021-10-28 2024-09-04 UCB Biopharma SRL Nukleinsäurekonstrukte, virale vektoren und virale partikel
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114480286B (zh) * 2022-02-16 2024-05-31 上海健士拜生物科技有限公司 无血清悬浮型lmh细胞系及其制备方法和应用
CN116656628A (zh) * 2023-07-31 2023-08-29 深圳市卫光生物制品股份有限公司 一种痘病毒载体疫苗的制备方法
EP4567102A1 (de) 2023-12-05 2025-06-11 Suprême Verfahren zur isolierung embryonaler stammzellen aus embryonalen vogelzellen
CN118956737A (zh) * 2024-07-17 2024-11-15 广州沃亘生物科技有限公司 一种长期维持df-1细胞活力的培养基及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388298A (en) 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
AU623922B2 (en) 1988-08-04 1992-05-28 Amrad Operations Pty. Limited In vitro propagation of embryonic stem cells
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
US5388680A (en) 1990-10-09 1995-02-14 Intellicall, Inc. Coin handling system with an improved coin chute
WO1993001276A1 (en) 1991-07-12 1993-01-21 Smithkline Beecham Corporation Continuous cell line and vaccine against avian coccidia
JPH05227947A (ja) 1992-01-14 1993-09-07 Rikagaku Kenkyusho 鳥類原始生殖細胞の分離方法
AU3597093A (en) 1992-01-27 1993-09-01 Embrex Inc. Gene transfer in poultry by introduction of embryo cells (in ovo)
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
WO1994003585A1 (en) 1992-08-04 1994-02-17 Commonwealth Scientific And Industrial Research Organisation A method for maintaining embryonic stem cells and avian factor useful for same
US5453357A (en) * 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5589458A (en) * 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
FR2726003B1 (fr) * 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5691200A (en) 1996-07-03 1997-11-25 The United States Of America As Represented By The Secretary Of Agriculture Method to produce granulocyte colony stimulating factor from immortalized avian T lymphocytes and method to produce immortalized cells
US5830723A (en) 1996-08-13 1998-11-03 Regents Of The University Of Minnesota Method for immortalizing chicken cells
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
US6103529A (en) 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
DK0841392T3 (da) 1996-11-12 2004-11-22 Pfizer Svækket levende Neospora vaccine
BR9811832A (pt) * 1997-08-04 2000-08-15 Univ Massachusetts Processo de cultivo, processo de melhorado de produção de aves quiméricas, e, linhagem de células eg de aves
DE69831958T2 (de) * 1997-08-04 2006-07-27 University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, Amherst Primordiale keimzellinie aus vögeln und verfahren zu deren langzeitkultivierung
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
ATE378398T1 (de) * 1999-02-11 2007-11-15 Hanmi Pharm Ind Co Ltd Pluripotente embryonale keimzellinie aus vögeln
DE60037819T2 (de) * 1999-08-27 2009-01-08 Invitrogen Corp., Carlsbad Metallbindende verbindungen und deren verwendung in zusammensetzungen für zellkulturmedien
DE19947407C2 (de) 1999-10-01 2002-08-01 Bayerische Motoren Werke Ag Datenbussystem für Kraftfahrzeuge
WO2002086073A2 (en) * 2001-04-20 2002-10-31 Memorial Sloan-Kettering Cancer Center Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP2287288B1 (de) 2002-07-09 2012-11-07 Baxter International Inc. Tierproteinfreies Zellkulturmedium
EP1500699A1 (de) 2003-07-22 2005-01-26 Vivalis Herstellung von Vacciniaviren mit Hilfe adhärenter oder nicht adhärenter Vogelzelllinien
DK1646715T3 (da) 2003-07-22 2010-08-16 Vivalis Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer
KR100552844B1 (ko) * 2003-12-31 2006-02-21 동부아남반도체 주식회사 반도체 소자의 제조 방법
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
WO2007135133A1 (en) 2006-05-19 2007-11-29 Vivalis Avian cell lines derived from primordial germ cells useful for the production of substances of interest
MX2009001477A (es) 2006-08-09 2009-02-18 Vivalis Metodo de produccion de un aviar transgenico utilizando celulas progenitoras embrionicas.
EP1985305A1 (de) 2007-04-24 2008-10-29 Vivalis Aus Entenembryonen gewonnene Stammzellkulturen zur Herstellung von Impfstoffen gegen Viren

Also Published As

Publication number Publication date
HK1142094A1 (en) 2010-11-26
US20120070893A9 (en) 2012-03-22
CN100562567C (zh) 2009-11-25
AU2003227820A1 (en) 2003-09-22
CN101676388B (zh) 2013-09-04
EP1483369B1 (de) 2008-09-10
JP2005525803A (ja) 2005-09-02
US20090239297A1 (en) 2009-09-24
JP5025888B2 (ja) 2012-09-12
US20100221825A1 (en) 2010-09-02
EP1992687A3 (de) 2009-03-25
PT1483369E (pt) 2008-12-17
JP5784521B2 (ja) 2015-09-24
DE60323468D1 (de) 2008-10-23
US20110294209A1 (en) 2011-12-01
CA2478125C (fr) 2013-05-07
FR2836924A1 (fr) 2003-09-12
EP1483369A1 (de) 2004-12-08
FR2836924B1 (fr) 2005-01-14
EP1992687A2 (de) 2008-11-19
AU2003227820B2 (en) 2008-04-03
WO2003076601A1 (fr) 2003-09-18
CA2478125A1 (fr) 2003-09-18
US9382513B2 (en) 2016-07-05
SI1483369T1 (sl) 2008-12-31
JP2012110344A (ja) 2012-06-14
EP1992687B1 (de) 2019-06-26
US20040058441A1 (en) 2004-03-25
DK1483369T3 (da) 2008-12-01
CN1649999A (zh) 2005-08-03
CN101676388A (zh) 2010-03-24
ES2312775T3 (es) 2009-03-01
WO2003076601A8 (fr) 2005-05-12

Similar Documents

Publication Publication Date Title
ATE408004T1 (de) Vögelzell-linien und deren verwendung zur herstellung interessanter biologischer substanzen
GB2432846B (en) Medium and culture of embryonic stem cells
DK1097988T3 (da) Fremgangsmåde til celledyrkning i monolag
DK1155116T3 (da) Anvendelse af kollagenase i fremstillingen af kulturer af neurale stamceller
EA199800835A1 (ru) Среда для культуры клеток млекопитающихся, способ ее получения и смесь компонентов, композиция, способы получения, продуцирования клонального роста, размножения и изменения фенотипа гепатоцитов in vitro, клетки, фармацевтический состав, способы получения рекомбинантной клетки и генного продукта, способы использования клеток, способ трансплантации гепатоцитов, способ испытания лекарственного препарата, способ поддержания жизнеспособности дифференцированных гепатоцитов
FI952022A7 (fi) Biologiset tekijät ja neuraaliset kantasolut
DE69720026D1 (de) Verfahren zur herstellung von d-aminosäuren durch direkte gärung
CN109777773A (zh) 一种从造血干细胞分化产生nk细胞的方法及其培养基
BR0316757A (pt) Composições de meio de cultura de célula, processo para a cultura de célula progenitoras e/ou tronco, processo para a produção de mioblastos, população de células, e uso de mioblastos
ATE479743T1 (de) Verfahren zur herstellung von zellkulturen aus biologischen präparaten für chemotherapeutische und andere assays
ATE510004T1 (de) In-vitro-techniken zur verwendung mit stammzellen
TW201311141A (zh) 微藻養殖模組
ATE449162T1 (de) Herstellung von tcr gamma delta t-zellen
ATE421573T1 (de) Verfahren zur herstellung von gamma delta t zellen
Kwon et al. Suspension culture of hematopoietic stem cells in stirred bioreactors
DE602006014534D1 (de) Herstellung und verwendung von basalmembranpartikeln
CN109679899A (zh) 一种人脂肪干细胞与脐带间充质干细胞成软骨能力的比较方法
JP2610997B2 (ja) 肝細胞培養方法
Ismet Gürhan et al. Serial cultivation of suspended BHK 21/13 cells in serum-reduced and serum-free medium supplemented with various membrane protective agents
JPS61124374A (ja) 酢酸からメタンを生成する微生物の培養法
CN1717478A (zh) 用于人类胚胎干细胞体外培养的饲养细胞层以及培养胚胎干细胞的方法
SU1279236A1 (ru) Способ непрерывного культивирования дрожжей
RU2001123409A (ru) Способ культивирования микроорганизмов Mycobacterium tuberculosis
CN106834127A (zh) 一种规模化高效培养聚球藻7002的方法
DE50307012D1 (de) Verfahren zur herstellung eines nerventransplantats

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1483369

Country of ref document: EP